Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease
Keywords:
Peripheral Inflammatory Cytokine Levels, Parkinson DiseaseAbstract
Background: The literature on peripheral inflammatory cytokine levels in Parkinson's disease (PD) reveals a multifaceted relationship between immune responses and disease pathology. Early foundational work emphasized the crucial roles of both central and peripheral inflammation in PD progression, positing that immune dysregulation may precede neurodegeneration (Su & J. Federoff, 2014). This perspective is supported by subsequent studies that delve into the role of α-synuclein in sustaining neuroinflammation, highlighting the dual nature of inflammatory processes that can initially appear beneficial yet ultimately lead to neuronal degeneration (Pessoa Rocha et al., 2015). Literature Review: Recent research has further established a correlation between elevated levels of peripheral inflammatory cytokines and the severity of motor symptoms in PD, suggesting that inflammation is not merely a byproduct of the disease but a significant contributor to its clinical manifestations (Diaz et al., 2022). Historical analyses have documented the presence of activated microglia and elevated cytokines in PD patients, linking these findings to the progression of motor symptoms (Heidari et al., 2022). The systemic nature of inflammation in PD has been underscored by studies that connect peripheral immune responses to central neuroinflammatory processes, indicating that PD affects various bodily systems (P. Williams et al., 2022). Moreover, the exploration of biomarkers of inflammation in both blood and cerebrospinal fluid (CSF) has illuminated the role of microglial activation and cytokine release in PD progression (Zimmermann & Brockmann, 2022).. Conclusion: In conclusion, the body of literature underscores the significance of peripheral inflammatory cytokines in the pathophysiology of PD. The interplay between central and peripheral immune responses is critical in understanding the disease's progression and symptomatology. Future research should continue to explore these interactions, as they hold potential for developing targeted therapeutic strategies aimed at mitigating inflammation and its effects on PD.
References
Su, X. & J. Federoff, H., 2014. Immune Responses in Parkinson's Disease: Interplay between Central and Peripheral Immune Systems. ncbi.nlm.nih.gov
Pessoa Rocha, N., Silva de Miranda, A., & Lúcio Teixeira, A., 2015. Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies. ncbi.nlm.nih.gov
Diaz, K., Kohut, M. L., Russell, D. W., & Stegemöller, E. L., 2022. Peripheral inflammatory cytokines and motor symptoms in persons with Parkinson's disease. ncbi.nlm.nih.gov
Heidari, A., Yazdanpanah, N., & Rezaei, N., 2022. The role of Toll-like receptors and neuroinflammation in Parkinson’s disease. ncbi.nlm.nih.gov
P. Williams, G., M. Schonhoff, A., Sette, A., & S. Lindestam Arlehamn, C., 2022. Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease. ncbi.nlm.nih.gov
Zimmermann, M. & Brockmann, K., 2022. Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease. ncbi.nlm.nih.gov
Dzamko, N., 2023. Cytokine activity in Parkinson’s disease. ncbi.nlm.nih.gov
Published
Issue
Section
License
Copyright (c) 2024 Jessica, Johan (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
